Resource Center

Go back to Resource Center

Safety and Efficacy of a Calcineurin-Inhibitor Avoidance Regimen in Pediatric Renal Transplantation


Journal Article

Harmon, W.; Meyers, K.; Ingelfinger, J.; McDonald, R.; McIntosh, M.; Ho, M.; Spaneas, L.; Palmer, J.; Hawk, M.; Geehan, C.; Tinckam, K.; Hancock, W.; Sayegh, M.

J Am Soc Nephrol




Adolescent; Calcineurin; Child; Female; Glomerular filtration rate; Graft Rejection; Graft Survival; Immunosuppressive Agents; kidney transplantation; Male; Pilot Projects; Time Factors; Treatment Outcome

Thirty-four children were entered into a pilot trial of calcineurin inhibitor avoidance after living-donor kidney transplantation, the CN-01 study. Patients were treated with anti-CD25 mAb, prednisone, mycophenolate mofetil, and sirolimus. Twenty patients were maintained on the protocol for up to 3 yr of follow-up. One enrolled patient did not receive the transplant because of a donor problem, eight terminated because of one or more rejection episodes, four terminated because of adverse events, and one was lost to follow-up. Two grafts were lost, one as a result of chronic rejection and the other as a result of posttransplantation lymphoproliferative disorder. There were no deaths. The 6- and 12-mo acute rejection rates were 21.8 and 31.5%, respectively. GFR were stable throughout the course of the study, with a slight downward trend by 6 mo after transplantation followed by a slight upward trend to a mean of 70 ml/min thereafter. Early surveillance graft biopsies frequently showed focal interstitial mononuclear cellular infiltrates without overt vasculitis or tubulitis, but these infiltrates disappeared without treatment. Anti-HLA class I and II antibodies were detected in three patients before transplantation, and all three had acute rejections, including the two patients who lost their grafts. De novo anti-HLA Ab production occurred in only one patient after transplantation. There were two episodes of Epstein Barr virus-related posttransplantation lymphoproliferative disorder, one of which developed after the patient had been terminated from the study. It is concluded that calcineurin inhibitor-free immunosuppression can be safe and effective in pediatric living-donor renal transplantation. However, further modifications that are designed to lessen early rejection rates and decrease complications should be tested before this approach is used routinely.

Go back to Resource Center